We restricted our searches to reports published after Jan 1, 1996, in English. We did several searches of PubMed using the search term “tuberculosis” plus “clinical trials”, “biomarkers”, and “drug development”, and individual searches for each of the drugs Q203, SQ109, TBA-354, bedaquiline, delamanid, levofloxacin, moxifloxacin, pretomanid, pyrazinamide, rifapentine, rifampicin, and sutezolid (PNU-100480), and compounds identified by the Stop TB Partnership Working Group for New TB Drugs
ReviewTuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
Introduction
WHO estimated that in 2014, 9·6 million people (5·4 million men, 3·2 million women, and 1 million children) fell ill with tuberculosis worldwide.1 The resulting 1·5 million deaths made tuberculosis the leading infectious cause of death globally.1 WHO further estimated 480000 cases (and 190000 deaths) were multidrug resistant (MDR; defined as resistant at a minimum to rifampicin and isoniazid; figure 1), and only a quarter of these cases were reported. An estimated 9·7% of cases of MDR tuberculosis were extensively drug resistant (XDR; defined as MDR plus additional resistance to at least one fluoroquinolone and one second-line injectable drug), and have been reported in 105 countries.1 In 2014, MDR tuberculosis accounted for 3·3% of new tuberculosis cases and 20% of previously treated cases.1 Only half of these patients will successfully complete treatment. Of those patients with outcome data, death (16%), loss to follow-up (16%), and treatment failure (10%) are common1 due to weaknesses in current regimens, national programmes, and operational challenges. MDR tuberculosis thus constitutes a major threat to global public health security. WHO's 2015 annual tuberculosis report1 states that “without new tuberculosis drugs and regimens, it will be very difficult to improve treatment outcomes in the near future”, adding “intensified research and development is one of the three pillars of WHO's Post-2015 Global Tuberculosis Strategy, and will play a crucial role in accelerating the reductions in tuberculosis incidence and mortality required to reach global tuberculosis targets by 2035”.
Many unmet medical needs exist for all forms of tuberculosis (panel). In this Review we describe how these needs can be addressed by recent developments in new and repurposed antimicrobial drugs and host-directed therapies, advances in biomarkers, strategies for regimen development, and opportunities afforded by regulatory innovation.
Section snippets
New and repurposed antimicrobial drugs
Regimens comprising entirely new drugs would be an important therapeutic advance, because they would reduce the present requirement for drug-susceptibility testing, thus simplifying patient care. The current tuberculosis antimicrobial drug pipeline shows eight drugs in phase 2–3 trials (figure 2). Two new drugs (bedaquiline and delamanid) are in confirmatory phase 3 trials, having received accelerated approvals for MDR tuberculosis based on phase 2 data in 2012, and 2014, respectively. However,
Host-directed therapeutics to eradicate infection and prevent lung damage
Scientific interest has recently increased in targeting of host factors to identify new treatments for MDR tuberculosis. Host-directed therapies (HDTs)—including new and repurposed drugs, biologics, and cellular therapies—have been proposed to shorten treatment duration, prevent resistance, and reduce lung injury, by promoting autophagy, antimicrobial peptide production, other macrophage effector mechanisms, and inhibiting mechanisms causing lung inflammation and matrix destruction.45, 46, 47
Advances in tuberculosis biomarkers
Biomarkers are measurable characteristics that can form the basis of surrogate endpoints, thereby accelerating drug development.73 However, progress in tuberculosis biomarkers has been slow.74, 75, 76 In 2015, a blueprint identified important research steps for advances in this area and emphasised collaboration and harmonisation of efforts.77 Four areas of particular interest for new tuberculosis regimens are sputum-culture status, PET, whole-blood bactericidal activity, and gene expression
Shortening of treatment in drug-susceptible tuberculosis
Relapse (the epigenetic persistence and subsequent reactivation of drug-susceptible but phenotypically tolerant, non-replicating bacilli) is the most common adverse clinical outcome in patients with drug-sensitive tuberculosis. The risk of relapse increases as the duration of treatment is reduced.80 Identification of shorter regimens that do not unacceptably increase the relapse risk has been a major research focus.
Efforts to shorten treatment have so far been diverse. Some trials have
Improvement of outcomes in patients with MDR tuberculosis
By contrast with drug-susceptible tuberculosis, poor outcomes in MDR tuberculosis more often are representative of treatment failure rather than relapse.101 Treatment failure precludes patient relapse.102 Relapses are less common in MDR tuberculosis than drug-sensitive tuberculosis, even after accounting for this competing endpoint.103 However, relapse will likely become more important in MDR tuberculosis trials as more effective regimens are studied and shorter treatment durations are judged.
Innovative strategies for new drugs, regimens, and research capacity in MDR tuberculosis
These previously stated observations illustrate the challenges faced by tuberculosis drug developers. In drug-sensitive tuberculosis, researchers must contend with a 6-month regimen that is relatively well tolerated and efficacious in trial conditions, even though it has been difficult to implement in real-world settings and yet more difficult to improve. In MDR tuberculosis, researchers must contend with control regimens requiring up to 3 years of treatment and follow-up, consisting of drugs
Search strategy and selection criteria
References (118)
- et al.
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Lancet
(2015) - et al.
Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial
Lancet
(1999) - et al.
Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort
Lancet
(2010) - et al.
Chronic obstructive airways disease following treated pulmonary tuberculosis
Respir Med
(1989) - et al.
Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis
Lancet Infect Dis
(2013) - et al.
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism
Cell
(2011) - et al.
Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis
Cell Host Microbe
(2011) - et al.
Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components
J Biol Chem
(2008) - et al.
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions
Leuk Res
(2014) - et al.
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology
Am J Pathol
(2011)